MedTrace Logo

RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination

NCT04951336 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-08-17

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of two polypore mushrooms, Fomitopsis officinalis and Trametes versicolor (FoTv), for use as an adjunct to vaccination for COVID-19 in a general population at the time of COVID-19 vaccination.

Conditions

  • COVID-19 Vaccination

Interventions

DIETARY_SUPPLEMENT

FoTv

Fomitopsis Officinalis and Trametes Versicolor

Sponsors & Collaborators

Principal Investigators

  • Andrew Shubov, MD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-10
Primary Completion
2022-01-21
Completion
2022-07-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04951336 on ClinicalTrials.gov